The patent was upheld following a modification of the infringed patent claim. The nullity cases on the rest of the two Aerocrine patents remain pending prior to the Munich Courtroom.. Aerocrine announces positive outcome of its patent proceedings against Medisoft Aerocrine Abdominal today announced the positive outcome of it is patent proceedings against Medisoft P.A.E. At the Courtroom of Selling point of Dusseldorf and the Federal Patent Court of Munich. These European patents also cover Belgium, Switzerland, Spain, France, United Kingdom, Ireland, Italy, Netherlands and Sweden. The judgments were subsequently appealed by Medisoft and Medisoft also filed nullity proceedings against the three Aerocrine patents in Germany.A complete of 7 of 463 patients had a relapse by post-treatment week 12, of whom 5 had a relapse at or before the visit at post-treatment week 4. Each one of the eight sufferers who had virologic failing during treatment or relapse had at least one amino acid variant that was recognized to confer resistance to among the three direct-acting antiviral agents included in the program. The most regularly detected variants in the seven patients with HCV genotype 1a infection during virologic failure during treatment or relapse had been D168V in the protein NS3, M28T and Q30R in the protein NS5A, and S556G in the protein NS5B. The single affected individual with HCV genotype 1b infection who had relapse acquired variants Y56H and D168V in the protein NS3, Y93H and L31M in the protein NS5A, and S556G in the protein NS5B at the right time of relapse.